> Details

Vollbach, Kristina; Tenbrock, Klaus; Wagner, Nobert; Horneff, Gerd; Klein, Ariane; Foeldvari, Ivan; Haas, Johannes-Peter; Aries, Peer; Gauler, Georg; Striesow, Frank; Hoff, Paula; Scholz, Christine; Tatsis, Stefanie; Seipelt, Eva; Klotsche, Jens; Minden, Kirsten

Outcome of adult patients with JIA treated with the biosimilar Benepali®: results of the biologic register JuMBO

Reference
management

Bookmarks

Remove from
bookmarks

Share this on Whatsapp

Close

Bookmarks



You can manage bookmarks using lists, please log in to your user account for this.
  • Media type: E-Article
  • Title: Outcome of adult patients with JIA treated with the biosimilar Benepali®: results of the biologic register JuMBO
  • Contributor: Vollbach, Kristina; Tenbrock, Klaus; Wagner, Nobert; Horneff, Gerd; Klein, Ariane; Foeldvari, Ivan; Haas, Johannes-Peter; Aries, Peer; Gauler, Georg; Striesow, Frank; Hoff, Paula; Scholz, Christine; Tatsis, Stefanie; Seipelt, Eva; Klotsche, Jens; Minden, Kirsten
  • Published: Springer Science and Business Media LLC, 2022
  • Published in: Arthritis Research & Therapy, 24 (2022) 1
  • Language: English
  • DOI: 10.1186/s13075-022-02968-7
  • ISSN: 1478-6362
  • Origination:
  • Footnote:
  • Description: Abstract Background To analyze therapy adherence, safety, and outcome in adult patients with juvenile idiopathic arthritis (JIA) treated with the etanercept biosimilar Benepali® (Biogen Inc, Cambridge, USA). Methods Data from the prospective registry, JuMBO (Juvenile arthritis MTX/Biologics long-term Observation), were used for the analysis. JuMBO is a long-term observational cohort study. It follows adult patients with JIA who were formerly included in the national JIA biologic register (BiKeR Registry). Both registries provide individual trajectories of clinical data and outcomes from childhood to adulthood in JIA patients treated with disease-modifying anti-rheumatic drugs (DMARDs). Results Eighty-three patients from the German JuMBO registry were treated with Benepali®. Of these, 74% had switched from Enbrel® (Pfizer Inc., NYC, USA) the originator of etanercept to Benepali® for cost reasons. Therapy survival of patients treated with Benepali® in comparison to Enbrel® in patients matched by significant parameters was comparable. Adverse events (AE) were reported in 25.3% and serious adverse events (SAE) in 9.6% of patients. Physicians rated no SAE causative related to Benepali®. The majority of SAEs were surgical/medical procedures and there was only one infection. All efficacy parameters (cJADAS-10, Physician Global Assessment, number of joints with active arthritis, patients’ overall well-being, pain, and HAQ) demonstrated improvement over 24 months (p-values were not significant). 9.6% of patients permanently discontinued Benepali® because of an AE. Conclusions Tolerability and effectiveness of the biosimilar Benepali® were satisfactory and therapy survival was comparable to the originator. Further data on therapy with biologics and biosimilars such as Benepali® must be collected by registries such as BiKeR and JuMBO in order to optimize therapy and patient outcomes and to reduce costs in the health system in the long term.
  • Access State: Open Access